Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin-and GABA-dependent

Pharmacological Reports

Volumn 63, Issue 4, 2011, Pages 880-887

  Stachowicz, Katarzyna ^a   Wierońska, Joanna ^a   Domin, Helena ^a   Chaki, Shigeyuki ^b   Pilc, Andrzej ^a,c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Anxiety; Conflict drinking Vogel test; MGS0039; Rats

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 AMINOBUTYRIC ACID; DIAZEPAM; FLUMAZENIL; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GABAERGIC SYSTEM; MALE; NONHUMAN; RAT; SEROTONINERGIC SYSTEM; TRANQUILIZING ACTIVITY;

EID: 80053356693     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70603-X     Document Type: Article

References (42)

1. 2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[ 1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem, 1997, 40, 2762-2769.
2. 1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. Eur J Pharmacol, 1997, 333, 147-157.
3. 1A receptor agonist and antagonist on the 5-hydroxytryptamine release in the central nucleus of the amygdala: a microdialysis study with flesinoxan and WAY 100635. Naunyn Schmiedebergs Arch Pharmacol, 1997, 355, 347-353.
4. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N Yoshimizu T et al.: MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology, 2004, 46, 457-467. (Pubitemid 38224431)
5. Chojnacka-Wójcik E, Kłodzinska A, Pilc A: Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs, 2001, 2, 1112-1119. (Pubitemid 32782621)
6. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors Annu Rev Pharmacol Toxicol, 1997, 37, 205-237. (Pubitemid 27238875)
7. Czyrak A, Czepiel K, Maćkowiak M, Chocyk A, Wȩdzony K: Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res, 2003, 989, 42-51. (Pubitemid 37281400)
8. Davis M, Walker DL, Miles L, Grillon C: Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology, 2010, 35, 105-135.
9. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology, 2008, 33, 1603-1610. (Pubitemid 351684700)
10. Fletcher A, Bill DJ, Bill SJ, Cliffe IA, Dover GM, Forster EA, Haskins JT et al.: WAY 100635: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmacol, 1993, 237, 283-291. (Pubitemid 23201838)
11. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M et al.: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97. (Pubitemid 351355090)
12. Haefely W, Kulcsár A, Möhler H: Possible involvement of GABA in the central actions of benzodiazepines. Psychopharmacol Bull, 1975, 11, 58-59.
13. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther, 1998, 284, 651-660. (Pubitemid 28086655)
14. Hensler JG: Serotonergic modulation of the limbic system. Neurosci Biobehav Rev, 2006, 30, 203-214.
15. Hoyer D, Clarke OE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR et al.: VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev, 1994, 46, 157-203. (Pubitemid 24185150)
16. Jenck F, Bös M, Wichmann J, Stadler H, Martin JR, Moreau JL: The role of 5-HT2C receptors in affective disorders. Expert Opin Investig Drugs, 1998, 7, 1587-1599. (Pubitemid 28451656)
17. Iijima M, Shimazaki T, Ito A, Chaki S: Effects of metabotropic glutamate 2/3 receptor antagonists in the stressinduced hyperthermia test in singly housed mice. Psychopharmacology, 2007, 190, 233-239. (Pubitemid 46011183)
18. Karreman M, Moghaddam B: Effect of a pharmacological stressor on glutamate efflux in the prefrontal cortex. Brain Res, 1996, 716, 180-182. (Pubitemid 26156607)
19. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okujama S, Yasuhara A, Nakazato A: Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett, 2005, 378, 131-134. (Pubitemid 40386858)
20. Kent JM, Coplan IO, Gorman JM: Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry, 1998, 44, 812-824. (Pubitemid 28520220)
21. Kinoshita A, Shigemoto R, Ohishi H, van der Putten H, Mizuno N: Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study. J Comp Neurol, 1998, 393, 332-352. (Pubitemid 28164590)
22. Kłodzinska A, Bijak M, Tokarski K, Pilc A: Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav, 2002, 73, 327-332. (Pubitemid 34765571)
23. Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A: Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology, 1999, 38, 1831-1839. (Pubitemid 29509721)
24. Lowy MT, Gault L, Yamamoto BK: Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. J Neurochem, 1993, 61, 1957-1960. (Pubitemid 23317225)
25. Lowy MT, Wittenberg L, Yamamoto BK: Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem, 1995, 65, 268-274.
26. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther, 2000, 292, 76-87.
27. Millan MJ: The neurobiology and control of anxious states. Prog Neurobiol, 2003, 70, 83-244.
28. Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R: Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res, 1994, 655, 251-254. (Pubitemid 24263017)
29. Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, Nakamura M et al.: Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0]hexane-2,6- dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem, 2004, 47, 4570-4587. (Pubitemid 39096843)
30. Ohishi H, Ogawa-Meguro R, Shigemoto R, Kaneko T, Nakanishi S, Mizuno N: Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron, 1994, 13, 55-66. (Pubitemid 24238414)
31. Pałucha A, Pilc A: Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther, 2007, 115, 116-147. (Pubitemid 46992810)
32. Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A: On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl), 2010, 212, 523-535.
33. Pin JP, Duvoisin R: The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995, 34, 1-26.
34. Pollard GT, Howard JL: Effects of drugs on punished behavior: pre-clinical test for anxiolytics. Pharmacol Ther, 1990, 45, 403-424. (Pubitemid 20003441)
35. Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F: Expression of serotonin 1A and serotonin 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex, 2004, 14, 1100-1109. (Pubitemid 39258165)
36. Schoepp DD: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther, 2001, 299, 12-20.
37. Shimazaki T, Lijima M, Chaki S: Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Eur J Pharmacol, 2004, 501, 121-125. (Pubitemid 39298944)
38. Stachowicz K, Chojnacka-Wójcik E, Kłak K, Pilc A: Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology, 2007, 52, 306-312. (Pubitemid 46123350)
39. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov, 2005, 4,131-144. (Pubitemid 40277494)
40. Vogel JR, Beer B, Clody DE: A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology, 1971, 21, 1-7.
41. Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldt M, Corbett R: Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl), 1993, 112, 195-198. (Pubitemid 23278278)
42. Yoshimizu T, Shimazaki T, Ito A, Chaki S: An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models on rats. Psychopharmacology, 2006, 186, 587-593. (Pubitemid 43855846)